
SI Stock Forecast & Price Target
SI Analyst Ratings
Bulls say
Shoulder Innovations Inc. demonstrated a robust performance in Q2 2025, achieving total revenue of $11.8 million, which reflects a significant 58% increase and surpasses estimates by $1.8 million. The company has effectively enhanced its balance sheet while benefiting from higher average selling prices and strong surgeon adoption of its implant portfolio, indicating a sustainable growth trajectory. With an anticipated growth of new surgeons at approximately 11 per quarter and a promising market runway ahead, the foundation for continued top-line expansion is solidified.
Bears say
Shoulder Innovations Inc. is experiencing significant financial challenges, reflected by an adjusted EBITDA loss of $7.5 million, which was $400,000 worse than previous models suggested. Key issues contributing to a negative outlook include slower than anticipated product adoption by new surgeons, lower shoulder market growth rates, and unexpectedly high operating expenses, which exceeded projections by approximately $900,000 due to increased headcount and legal costs. Additionally, the company's reliance on a limited number of surgeons for product uptake raises concerns about future revenue growth and market penetration, further exacerbated by the broader market's potential for ASP degradation.
This aggregate rating is based on analysts' research of Shoulder Innovations LLC and is not a guaranteed prediction by Public.com or investment advice.
SI Analyst Forecast & Price Prediction
Start investing in SI
Order type
Buy in
Order amount
Est. shares
0 shares